Results 151 to 160 of about 926 (181)

Would you be interested in DMPA-SC? An implementation project in two urban primary care clinics

Contraception, 2022
Self-administered DMPA-SC has similar efficacy to DMPA-IM with potential benefits. We conducted an implementation study to assess interest in and successful use of DMPA-SC for patients using DMPA-IM. Four physicians telephoned patients with DMPA-IM on their medication list in two urban primary care clinics and offered counseling and prescriptions to ...
Christina Miles
exaly   +3 more sources

Contraceptive efficacy and safety of DMPA-SC

Contraception, 2004
DMPA-SC 104 mg/0.65 mL is a new, low-dose subcutaneous (SC) formulation of Depo-Provera contraceptive injection (150 mg/mL medroxyprogesterone acetate injectable suspension) that provides efficacy, safety and immediacy of onset equivalent to Depo-Provera intramuscular (IM) injection.
J, Jain, A J, Jakimiuk, F R, Bode, D, Ross, A M, Kaunitz   +4 more
exaly   +3 more sources

Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC)

Contraception, 2022
Depot medroxyprogesterone acetate (DMPA) is a highly-effective, injectable contraceptive method that requires injections every 12 to 15 weeks. The need for return visits to a healthcare provider may present barriers to access, use, and continuation of DMPA.
Julia E, Kohn, Elise D, Berlan, Jennifer H, Tang, Anitra, Beasley   +3 more
openaire   +2 more sources

Acceptability of Contraceptive Self-Injection with DMPA-SC Among Adolescents in Gulu District, Uganda

International Perspectives on Sexual and Reproductive Health, 2017
In Uganda, an estimated one in four adolescent women have begun childbearing. Many adolescent pregnancies are unintended because of substantial barriers to contraceptive access. The injectable contraceptive is the most commonly used method in Uganda, and a new subcutaneous version offers the possibility of reducing access barriers by offering a self ...
Jane, Cover, Jeanette, Lim, Allen, Namagembe, Justine, Tumusiime, Jennifer Kidwell, Drake, Carie Muntifering, Cox   +5 more
openaire   +2 more sources

Effect of subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women

Contraception, 2012
The effects of subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) injection on androgenic markers in obese women have not previously been studied.Five normal-weight [body mass index (BMI)=18.5-24.9 kg/m²], five obese (BMI=30-39.9 kg/m²) and five extremely obese (BMI≥40 kg/m²) women were recruited for this prospective experimental study in which ...
Penina, Segall-Gutierrez, Joanna, Du, Chunying, Niu, Marshall, Ge, Ian, Tilley, Kelly, Mizraji, Frank Z, Stanczyk   +6 more
openaire   +2 more sources

National Policy Landscape Analysis on DMPA-SC: Pakistan Final Report

2023
Azmat, Syed Khurram, Awan, Muhammad Ali
openaire   +1 more source

Subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) use in obese and morbidly obese women: incidence of ovulation and follicular development

2015
Background: Subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) has not been studied in the morbidly obese population. The purpose of this 26-week prospective experimental study is to determine incidence of ovulation and follicular development among obese and morbidly obese women after DMPA-SC.
openaire   +1 more source

Science Says: Self-administered DMPA-SC is safe, feasible, and acceptable

2023
openaire   +1 more source

DMPA-IM, DMPA-SC: Side Effect Differences Few

Pediatric News, 2010
openaire   +1 more source

Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model

Viruses, 2022
Jiafen Hu, Vonn Walter, Nancy M Cladel
exaly